The cloning trade is contracting—sarcastically, maybe.
On Tuesday, Colossal Biosciences introduced that it has acquired ViaGen Pets and Equine, an animal cloning agency, marking Colossal’s first acquisition because it launched in 2021.
Texas-based Colossal Biosciences is greatest identified for its controversial “de-extinction” endeavors, which contain efforts to get better species which have died out. Earlier this yr, the corporate claimed to have “introduced again” dire wolves, an assertion that was disputed by some consultants, because the animals have been created by modifying the DNA of current grey wolves.
The corporate has additionally sparked debates concerning the ethics of bringing species again from extinction, or if what it’s doing is the truth is “de-extinction” in any respect.
Both method, Colossal has attracted vital curiosity from high-powered buyers, lately raising $120 million to try to resurrect the dodo. Its acquisition of ViaGen provides much more genetic firepower to its arsenal.
“Colossal is thrilled to welcome ViaGen, the world’s main cloning firm, into our portfolio,” mentioned Ben Lamm, founder and CEO of Colossal, in an announcement supplied to Quick Firm. “No different firm comes near what ViaGen has achieved. Their unmatched experience and cloning know-how stack have change into the world’s normal and their software of those crucial and proprietary applied sciences to endangered species conservation makes them a useful companion in advancing our international de-extinction and species preservation mission.”
Phrases of the acquisition weren’t disclosed.
Entry to breakthrough applied sciences
ViaGen, a Texas-based firm based in 2002, will proceed to function beneath its current management and broaden its endangered species cloning exercise.
Maybe probably the most fascinating ingredient at play is ViaGen’s unique licensing and entry to the breakthrough applied sciences developed by the Roslin Institute of Edinburgh—similar to those who cloned Dolly the sheep, the primary cloned mammal.
“Partnering with Colossal Biosciences presents a unprecedented alternative to use our superior cryopreservation and cloning methods to the formidable objectives of de-extinction and species restoration,” mentioned Dr. Shawn Walker, Ph.D., ViaGen’s chief science officer and identified cloning skilled, in an announcement.
Colossal has additionally attracted a steady of movie star buyers. Retired NFL star Tom Brady, as an illustration, labored with the corporate to clone his household’s canine, and mentioned in an announcement that he’s “excited how Colossal and ViaGen’s tech collectively will help each households shedding their beloved pets whereas serving to to avoid wasting endangered species.”
The potential to avoid wasting endangered species is one thing that has others excited, too. Colossal shared an announcement from filmmaker Peter Jackson, who mentioned, “These two corporations collectively give humanity an actual shot at saving the planet’s biodiversity.”
